Targeting Tumor Microenvironment for Cancer Therapy.
作者： Catarina Roma-Rodrigues , Rita Mendes , Pedro Baptista , Alexandra Fernandes
DOI: 10.3390/IJMS20040840
关键词:
摘要: Cancer development is highly associated to the physiological state of the tumor microenvironment (TME). Despite the existing heterogeneity of tumors from the same or from different anatomical locations, common features can be found in the TME maturation of epithelial-derived tumors. Genetic alterations in tumor cells result in hyperplasia, uncontrolled growth, resistance to apoptosis, and metabolic shift towards anaerobic glycolysis (Warburg effect). These events create hypoxia, oxidative stress and acidosis …
mdpi.com
sci-hub.se 参考文章(208)
Barbara Fingleton, CMT-3. CollaGenex. Current opinion in investigational drugs. ,vol. 4, pp. 1460- 1467 ,(2003)
John W Haycock, None, 3D cell culture: a review of current approaches and techniques. Methods of Molecular Biology. ,vol. 695, pp. 1- 15 ,(2011) , 10.1007/978-1-60761-984-0_1
EMIL FREI, EMIL J. FREIREICH, Progress and Perspectives in the Chemotherapy of Acute Leukemia Advances in Chemotherapy#R##N#Volume 2. ,vol. 2, pp. 269- 298 ,(1965) , 10.1016/B978-1-4831-9930-6.50011-3
Jun Wang, Xiao Dong He, Nan Yao, Wen Jia Liang, You Cheng Zhang, A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Canadian Journal of Gastroenterology & Hepatology. ,vol. 27, pp. 351- 363 ,(2013) , 10.1155/2013/417894
Peter Vaupel, Arnulf Mayer, Hypoxia in Tumors: Pathogenesis-Related Classification, Characterization of Hypoxia Subtypes, and Associated Biological and Clinical Implications Advances in Experimental Medicine and Biology. ,vol. 812, pp. 19- 24 ,(2014) , 10.1007/978-1-4939-0620-8_3
Ion S. Jovin, Yan Huang, Jennifer E. Ziello, Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale Journal of Biology and Medicine. ,vol. 80, pp. 51- 60 ,(2007)
Georgina N. Masoud, Wei Li, HIF-1α pathway: role, regulation and intervention for cancer therapy Acta Pharmaceutica Sinica B. ,vol. 5, pp. 378- 389 ,(2015) , 10.1016/J.APSB.2015.05.007
Alessandra De Remigis, Tanja D De Gruijl, Jennifer N Uram, Schey‐Cherng Tzou, Shintaro Iwama, Monica V Talor, Todd D Armstrong, Saskia JAM Santegoets, Susan F Slovin, Lei Zheng, Daniel A Laheru, Elizabeth M Jaffee, Winald R Gerritsen, Alfons JM Van Den Eertwegh, Dung T Le, Patrizio Caturegli, None, Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. International Journal of Cancer. ,vol. 136, pp. 127- 137 ,(2015) , 10.1002/IJC.28973
Bastian Schilling, Antje Sucker, Klaus Griewank, Fang Zhao, Benjamin Weide, André Görgens, Bernd Giebel, Dirk Schadendorf, Annette Paschen, Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. International Journal of Cancer. ,vol. 133, pp. 1653- 1663 ,(2013) , 10.1002/IJC.28168
Evan J Lipson, William H Sharfman, Shuming Chen, Tracee L McMiller, Theresa S Pritchard, January T Salas, Susan Sartorius-Mergenthaler, Irwin Freed, Sowmya Ravi, Hao Wang, Brandon Luber, Janice Davis Sproul, Janis M Taube, Drew M Pardoll, Suzanne L Topalian, None, Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. Journal of Translational Medicine. ,vol. 13, pp. 214- 214 ,(2015) , 10.1186/S12967-015-0572-3